Fo­cus­ing on cut­ting down sup­ply is­sues, ra­di­oli­gand biotech Ad­van­Cell rais­es $12M

In March, No­var­tis’ ra­di­oli­gand drug Plu­vic­to was ap­proved for PS­MA-pos­i­tive metasta­t­ic prostate can­cer, a mile­stone in the slow­ly bub­bling field of tar­get­ed ra­di­a­tion ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER